Quarterly report pursuant to Section 13 or 15(d)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)

v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES          
Share-based Payment Arrangement, Expense       $ 1,624,309 $ 3,158,487
Revenue $ 0   $ 0 0 20,000
Total internal and external clinical studies study expens       $ 1,337,303 $ 3,308,000
Common shares issuable upon the exercise of outstanding stock options and warrants 6,164,573   2,969,338 6,164,573 2,969,338
Potentially dilutive securities       52,957  
Costs directly related to public securities offering   $ 143,377      
Current federal deposit insurance       $ 250,000  
Common shares from convertible debentures and related accrued interest     $ 957,234   $ 957,234